SRL
KAPA

Scientech Research LLC’s Kairos Pharma KAPA Stock Holding History

Scientech Research LLC’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48,198
Closed -$45.1K – 905
2025
Q1 		$45.1K Buy
+48,198
New +$61.7K 0.01% 523

Other funds holding KAPA

SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Scientech Research LLC's KAPA Position: Q2 2025 in Review

Scientech Research LLC sold out of Kairos Pharma (KAPA) in Q2 2025, closing a stake of 48,198 shares — an estimated $45.1K sold.

Scientech Research LLC first reported a position in KAPA in Q1 2025 and held it in 1 quarter. The position peaked at $45.1K in Q1 2025. 10 funds tracked by Wall St. Rank hold KAPA as of Q2 2025.

  • Scientech Research LLC reported no remaining Kairos Pharma position as of Q2 2025 after selling out during the quarter.
  • Scientech Research LLC sold 48,198 Kairos Pharma shares in Q2 2025, an estimated $45.1K.
  • Scientech Research LLC first reported a position in Kairos Pharma in Q1 2025 and held it in 1 quarter.
  • Scientech Research LLC's Kairos Pharma position peaked at $45.1K in Q1 2025.
  • 10 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2025.

Based on Scientech Research LLC's 13F filing for Q2 2025, filed 14 Aug 2025.